SAN
FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will announce its financial results for
the third quarter 2024 on Thursday, November
7, 2024, after the close of U.S.-based financial markets.
Howard Robin, President and Chief
Executive Officer, will host a conference call to review the
results beginning at 5:00 p.m. Eastern
Time/2:00 p.m. Pacific
Time.
The press release and live audio-only webcast of the conference
call can be accessed through a link that is posted on the Home Page
and Investors section of the Nektar website: http://ir.nektar.com/.
The web broadcast of the conference call will be available for
replay through December 7, 2024.
To access the conference call, please pre-register at Nektar
Earnings Call Registration. All registrants will receive dial-in
information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is
a clinical-stage biotechnology company focused on developing
treatments that address the underlying immunological dysfunction
in autoimmune and chronic inflammatory
diseases. Nektar's lead product candidate,
rezpegaldesleukin (REZPEG, or NKTR-358), is a
novel, first-in-class regulatory T cell stimulator
being evaluated in two Phase 2b
clinical trials, one in atopic dermatitis and one
in alopecia areata. Our pipeline also includes a
preclinical candidate NKTR-0165, which is a bivalent tumor necrosis
factor receptor type II agonist antibody.
Nektar, together with various partners, is also evaluating
NKTR-255, an investigational IL-15 receptor agonist
designed to boost the immune system's natural ability to
fight cancer, in several ongoing clinical trials. Nektar
is headquartered in San Francisco,
California. For further information, visit
www.nektar.com and follow us on LinkedIn.
Contacts:
For Investors:
Vivian Wu
of Nektar Therapeutics
(628)
895-0661
For Media:
Madelin
Hawtin
LifeSci
Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2024-on-thursday-november-7-2024-after-close-of-us-based-financial-markets-302293320.html
SOURCE Nektar Therapeutics
